Abstract
Clinical outcomes of patients with chronic myeloid leukemia (CML) have drastically improved with tyrosine kinase inhibitors (TKIs). However, one of the main challenges is the management of intolerance experienced by patients with CML treated with TKI, resulting in poorer disease control. This targeted literature review examined the association of intolerance to TKIs in CML and clinical, economic and humanistic outcomes in a real-world setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
